Home
>
US Stocks
>
Ardelyx Inc
Ardelyx Inc
ARDX

Ardelyx Inc (ARDX)

$1.1620%

1D

1W

1M

1Y

3Y

5Y

Key Stats

Open
$1.09
Today Low/High
$1.09 / $1.18
52 Week Low/High
$1.33 / $9.23
Market Cap
$151.58M

Company Details

Ardelyx is focused on discovering, developing, and commercializing innovative first-in-class medicines to enhance the lives of patients with kidney and cardiorenal diseases. Ardelyx is advancing tenapanor, a novel product candidate to control serum phosphorus in adult patients with CKD on dialysis, for which the company's NDA is currently under review by the FDA, with a PDUFA date of April 29, 2021. Ardelyx is also advancing RDX013, a potassium secretagogue, for the potential treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease and has an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. In addition, Ardelyx received FDA approval of IBSRELA® (tenapanor) on September 12, 2019. Ardelyx has established agreements with Kyowa Kirin in Japan, Fosun Pharma in China and Knight Therapeutics in Canada for the development and commercialization of tenapanor in their respective territories.
Organisation
Ardelyx Inc
Headquaters
Fremont, California, US
Employees
129
Industry
Health Technology
CEO
Michael Raab

Discover more

Frequently Asked Questions

What is Ardelyx Inc (ARDX) share price today?

Can Indians buy Ardelyx Inc (ARDX) shares?

How can I buy Ardelyx Inc (ARDX) shares from India?

Can Fractional shares of Ardelyx Inc (ARDX) be purchased?

What are the documents required to start investing in Ardelyx Inc (ARDX) stocks?

We are a SEBI registered investement advisor